Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial

医学 无容量 易普利姆玛 耐受性 内科学 索拉非尼 肝细胞癌 肿瘤科 随机对照试验 不利影响 外科 胃肠病学 癌症 免疫疗法
作者
Thomas C. C. Yau,Yoon‐Koo Kang,Tae‐You Kim,Anthony B. El-Khoueiry,Armando Santoro,Bruno Sangro,Ignacio Melero,Masatoshi Kudo,Ming‐Mo Hou,Ana María Matilla,Francesco Tovoli,Jennifer Jane Knox,Aiwu Ruth He,Bassel F. El‐Rayes,Mirelis Acosta-Rivera,Ho-Yeong Lim,Jaclyn Neely,Yun Shen,Tami Wisniewski,Jeffrey Anderson
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (11): e204564-e204564 被引量:1408
标识
DOI:10.1001/jamaoncol.2020.4564
摘要

IMPORTANCE: Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes compared with nivolumab monotherapy. OBJECTIVE: To assess efficacy and safety of nivolumab plus ipilimumab in patients with advanced HCC who were previously treated with sorafenib. DESIGN, SETTING, AND PARTICIPANTS: CheckMate 040 is a multicenter, open-label, multicohort, phase 1/2 study. In the nivolumab plus ipilimumab cohort, patients were randomized between January 4 and September 26, 2016. Treatment group information was blinded after randomization. Median follow-up was 30.7 months. Data cutoff for this analysis was January 2019. Patients were recruited at 31 centers in 10 countries/territories in Asia, Europe, and North America. Eligible patients had advanced HCC (with/without hepatitis B or C) previously treated with sorafenib. A total of 148 patients were randomized (50 to arm A and 49 each to arms B and C). INTERVENTIONS: Patients were randomized 1:1:1 to either nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm A); nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm B); or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (arm C). MAIN OUTCOMES AND MEASURES: Coprimary end points were safety, tolerability, and objective response rate. Duration of response was also measured (investigator assessed with the Response Evaluation Criteria in Solid Tumors v1.1). RESULTS: Of 148 total participants, 120 were male (81%). Median (IQR) age was 60 (52.5-66.5). At data cutoff (January 2019), the median follow-up was 30.7 months (IQR, 29.9-34.7). Investigator-assessed objective response rate was 32% (95% CI, 20%-47%) in arm A, 27% (95% CI, 15%-41%) in arm B, and 29% (95% CI, 17%-43%) in arm C. Median (range) duration of response was not reached (8.3-33.7+) in arm A and was 15.2 months (4.2-29.9+) in arm B and 21.7 months (2.8-32.7+) in arm C. Any-grade treatment-related adverse events were reported in 46 of 49 patients (94%) in arm A, 35 of 49 patients (71%) in arm B, and 38 of 48 patients (79%) in arm C; there was 1 treatment-related death (arm A; grade 5 pneumonitis). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, nivolumab plus ipilimumab had manageable safety, promising objective response rate, and durable responses. The arm A regimen (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks then nivolumab 240 mg every 2 weeks) received accelerated approval in the US based on the results of this study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01658878.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Orange的应助被zzj采纳,获得10
1秒前
科研通AI6.2的应助被匆匆采纳,获得10
1秒前
1秒前
2秒前
笨笨卡卡西完成签到,获得积分10
2秒前
3秒前
CipherSage的应助被研友_89e5G8采纳,获得10
3秒前
3秒前
3秒前
科研通AI65的应助被ge_jn采纳,获得10
4秒前
鹭江完成签到,获得积分10
4秒前
soory完成签到,获得积分10
4秒前
5秒前
江子川发布了新的文献求助10
5秒前
5秒前
江子川发布了新的文献求助10
5秒前
研友_VZG7GZ的应助被米兰小铁匠采纳,获得10
5秒前
tso关注了科研通微信公众号
5秒前
江子川发布了新的文献求助10
5秒前
aaaaasdsaf发布了新的文献求助10
6秒前
小熊维尼发布了新的文献求助20
6秒前
慕子默完成签到,获得积分10
7秒前
7秒前
左西完成签到 ,获得积分10
8秒前
江子川发布了新的文献求助10
8秒前
周华健发布了新的文献求助10
8秒前
zj发布了新的文献求助10
8秒前
酷波er的应助被Brave采纳,获得10
8秒前
江子川发布了新的文献求助10
9秒前
9秒前
777发布了新的文献求助10
9秒前
Jessica发布了新的文献求助10
11秒前
思源的应助被sasakiki采纳,获得10
11秒前
赘婿的应助被初见采纳,获得30
11秒前
11秒前
12秒前
内向晓旋完成签到,获得积分10
12秒前
Nefelibate完成签到,获得积分10
12秒前
Hello的应助被魏同心采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698